Provexis plc (AIM:PXS)

Market Cap	21.11M
Revenue (ttm)	871.27K
Net Income (ttm)	-603.80K
Shares Out	2.35B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,000,511
Average Volume	2,010,687
Open	0.8795
Previous Close	0.8450
Day's Range	0.8200 - 0.9500
52-Week Range	0.4000 - 0.9500
Beta	0.25
RSI	81.45
Earnings Date	Dec 31, 2025

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2024, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2023.